Author Archive: Roxan Olivas
Global Biopharmaceutical Leader to Usher C-Path in Next Phase of Growth and Innovation
Board names Dr. Daniel Jorgensen as Chief Executive OfficerContinue reading
C-Path’s European Nonprofit Appoints Managing Director and New Board Member to Expand Global Efforts
TUCSON, Ariz. and AMSTERDAM, September 20, 2022 — Critical Path Institute’s (C-Path) European nonprofit today announced the appointment of Cécile Ollivier M.S. as Managing Director – Europe and Robert Hemmings, M.S., to its Board of Directors.Continue reading
C-Path Awarded FDA Grant to Establish Public-Private Partnership to Advance Treatments for Rare Neurodegenerative Diseases
TUCSON, Ariz., Sept. 14, 2022 — Critical Path Institute (C-Path) has announced it will serve as the convener of the Critical Path for Rare Neurodegenerative Diseases (CP-RND), a new public-private partnership (PPP) to benefit people across multiple rare neurodegenerative diseases, supported by a grant from the U.S. Food and Drug Administration (FDA). The Agency announced the PPP today in a press release.Continue reading
C-Path’s Kristen Swingle Named President
Swingle joined C-Path in 2019 and was named interim president in 2021
TUCSON, Ariz., Sept. 8, 2022 — Critical Path Institute (C-Path) today announced that its Chief Operating Officer (COO) and Interim President, Kristen Swingle, M.S., has been named COO and President, effective immediately. Swingle has filled the interim President role since 2021, stewarding C-Path through growth and innovation, including the establishment of multiple national and global programs, a new European entity, a 50% staff increase, and a 90% increase in revenue.Continue reading
C-Path to Lead Pre-Consortium Aimed at Transforming, Accelerating Medical Product Development in Lysosomal Diseases
TUCSON, Ariz., Sept. 1, 2022 — Critical Path Institute (C-Path) today announced the launch of a pre-consortium collaboration focused on accelerating medical product development in lysosomal diseases, supported by a grant from the U.S. Food and Drug Administration (FDA).Continue reading
Upcoming Rare Disease Workshop Focuses on the Importance of Data Sharing in Drug Development
C-Path, NORD and FDA to host annual workshop September 13-14 to highlight the impact of their innovative data and analytics platform on rare disease drug developmentContinue reading
Oak Hill Bio Joins C-Path’s International Neonatal Consortium
TUCSON, Ariz., Aug. 24, 2022 — Critical Path Institute (C-Path) today announced that Oak Hill Bio (Oak Hill), a clinical-stage neonatology and rare disease therapeutics company, has become a member of its International Neonatal Consortium (INC).Continue reading
C-Path’s Dr. Amanda Klein Promoted to Transplant Therapeutic Consortium Executive Director
TUCSON, Ariz., July 14, 2022 — Critical Path Institute (C-Path) has named Amanda Klein, Pharm.D., as Executive Director for its Transplant Therapeutics Consortium (TTC) effective immediately.Continue reading
C-Path and Replica Analytics Collaboration Aims to Accelerate Rare Disease Research
NEW YORK, OTTAWA and TUCSON, Ariz., June 29, 2022 — Critical Path Institute (C-Path) and Replica Analytics, an Aetion company, announced today a new partnership that involves leveraging synthetic data to further catalyze the generation of actionable solutions to accelerate drug development for rare diseases.Continue reading